BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29853736)

  • 21. Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer.
    Lan Y; Pi W; Zhou Z; Meng Y; DanMei ; Xu Y; Xia X; WeiWang ; Yang H; Spring Kong FM
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110956. PubMed ID: 37751656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer.
    Elzagheid A; Emaetig F; Alkikhia L; Buhmeida A; Syrjänen K; El-Faitori O; Latto M; Collan Y; Pyrhönen S
    Anticancer Res; 2013 Aug; 33(8):3137-43. PubMed ID: 23898071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
    Hennequart M; Pilotte L; Cane S; Hoffmann D; Stroobant V; Plaen E; Van den Eynde BJ
    Cancer Immunol Res; 2017 Aug; 5(8):695-709. PubMed ID: 28765120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Indoleamine 2, 3-dioxygenase 1 (IDO1) and Tryptophanyl-tRNA Synthetase (WARS) in Gastric Cancer Molecular Subtypes.
    Lu S; Wang LJ; Lombardo K; Kwak Y; Kim WH; Resnick MB
    Appl Immunohistochem Mol Morphol; 2020; 28(5):360-368. PubMed ID: 31033497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer.
    Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Ann Surg; 2019 Jun; 269(6):1101-1108. PubMed ID: 31082908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival.
    Lynch KT; Gradecki SE; Kwak M; Meneveau MO; Wages NA; Gru AA; Slingluff CL
    Am J Surg Pathol; 2021 Jun; 45(6):787-795. PubMed ID: 33208630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer.
    Cesario A; Rocca B; Rutella S
    Curr Med Chem; 2011; 18(15):2263-71. PubMed ID: 21517752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer.
    Ferreira JM; Dellê H; Camacho CP; Almeida RJ; Reis ST; Matos YST; Lima AMR; Leite KRM; Pontes-Júnior J; Srougi M
    Int Urol Nephrol; 2020 Aug; 52(8):1477-1482. PubMed ID: 32152758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
    Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
    EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    Hamy AS; Tury S; Wang X; Gao J; Pierga JY; Giacchetti S; Brain E; Pistilli B; Marty M; Espié M; Benchimol G; Laas E; Laé M; Asselain B; Aouchiche B; Edelman M; Reyal F
    J Clin Oncol; 2019 Mar; 37(8):624-635. PubMed ID: 30702971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer.
    Ozawa T; Kazama S; Akiyoshi T; Murono K; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Morikawa T; Fukayama M; Watanabe T
    Ann Surg Oncol; 2014 Aug; 21(8):2650-8. PubMed ID: 24728738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients.
    Dimitriou N; Felekouras E; Karavokyros I; Alexandrou A; Pikoulis E; Griniatsos J
    BMC Cancer; 2018 Dec; 18(1):1202. PubMed ID: 30509242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
    Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.
    Ishihara S; Yamada Y; Iwasaki T; Yoshimoto M; Toda Y; Kohashi K; Yamamoto H; Matsumoto Y; Nakashima Y; Oda Y
    Oncol Rep; 2021 Jan; 45(1):379-389. PubMed ID: 33155664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
    Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
    J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
    Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
    Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota.
    Alvarado DM; Chen B; Iticovici M; Thaker AI; Dai N; VanDussen KL; Shaikh N; Lim CK; Guillemin GJ; Tarr PI; Ciorba MA
    Gastroenterology; 2019 Oct; 157(4):1093-1108.e11. PubMed ID: 31325428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.
    Bishnupuri KS; Alvarado DM; Khouri AN; Shabsovich M; Chen B; Dieckgraefe BK; Ciorba MA
    Cancer Res; 2019 Mar; 79(6):1138-1150. PubMed ID: 30679179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.